Medicare Advantage
Soon, ESRD patients will be permitted to enroll in Medicare Advantage (MA) plans, potentially bringing major changes to ESRD care and how patients experience it. DPC lobbied Congress to change the law to permit ESRD patients the choice to elect such plans. Under current restrictions, which will end in 2021, the only dialysis patients in MA plans are those whose kidneys failed while they were already enrolled in a plan.
Congress had previously enacted many changes to Medicare managed care that made MA plans more attractive relative to fee-for-service Medicare, including an out-of-pocket maximum that is lower than the cost sharing most dialysis patients are responsible for in a year. Medicare beneficiaries in MA plans do not need to purchase Medigap insurance, which will be of particular benefit to patients in states that do not mandate Medigap issuance to under-65 Medicare beneficiaries. Premiums for MA plans average about $30/month, far less expensive than Medigap supplements.
MA plans also have a reputation for coordinating the care of patients with complex needs. An insurer that keeps such patients out of the hospital will earn more money, aligning financial incentives to avoid complications. MA plans also have more flexibility to address patients’ individual needs than the relatively rigid and siloed fee-for-service program.
It is DPC’s expectation that some Medicare Advantage issuers will build on partnerships they already have with some large dialysis organizations to coordinate patients care. We are generally optimistic in anticipating that these programs will bring greater care coordination and improved outcomes. However, we recognize that unintended consequences are possible, and there is a long and unfortunate history of managed care organizations stinting on expensive care. CMS needs to be on top of this transition, to anticipate and prevent any problems for beneficiaries. A top DPC priority in the coming years will be ensuring that this transition brings a broad selection of high-quality choices for dialysis patients, and that insurers act in good faith and do not discourage high-cost patients from choosing or staying in their plans.
Related Information
DPC Commentary Discusses How Workforce Shortages Impact Patients
A commentary about workforce shortage issues authored by DPC Vice President of Public Policy Jackson Williams amplifies findings from this summer’s DPC member survey to explain how ESRD patients have been impacted. The article [...]
AJMC Contributor Article: Medicare’s Leadership Needs to Confront Our Shrinking US Workforce
Written by Jackson Williams, JD, DPC Vice President of Public Policy Medicare’s administered pricing system has never had to deal with labor scarcity before. Fifteen years ago, the Institute of Medicine issued [...]
Medicare Policy Proposal Jeopardizes Care for Those on Dialysis
CEOs of 3 kidney care organizations explain flaws in CMS' recent reimbursement proposal. In recent years, lawmakers have turned their attention to advancing health equity and creating opportunities for the improvement of historically underserved communities—and [...]
DPC Raises Alarm on Health Workforce Shortages
DPC’s letter commenting on this year’s ESRD Payment Rule warns that Medicare is not addressing workforce shortages that are impacting patient care. The letter reports the following findings from our recent member survey: 62% of [...]
DPC’s Letter to Hon. Chiquita Brooks-LaSure, Administrator for CMS, on End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Calendar Year (CY) 2024 Proposed Rule (CMS-1782-P)
August 18, 2023 Hon. Chiquita Brooks-LaSure, Administrator Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Calendar Year (CY) 2024 Proposed [...]
What Patients Should Know About Medicare’s New Immunosuppressive Drug Benefit
It had always seemed illogical that Medicare coverage for under-65 ESRD patients ends 36 months after a successful kidney transplant. Why would Medicare make a huge investment in a transplant and then stop paying [...]